01.10.2012 • NewsJan-Peter SanderBASFPeople

Jan-Peter Sander Named Senior Vice President of BASF Personal Care Europe Unit

Jan-Peter Sander (53) has been named Senior Vice President of BASF's business unit Personal Care Europe, and will take up the role on October 1, 2012.

Prior to his appointment, he held the same position at BASF' business unit Pigments and Resins Europe.

In his new position, Sander will be responsible for all areas of the business, including manufacturing, supply chain, technology, marketing and sales. He will also be in charge of ensuring that BASF's personal care business strategy continues to be successfully implemented in the future.

The business unit Personal Care Europe has been established after the acquisition of Cognis to bring together BASF's European personal care business activities and is part of BASF's Care Chemicals division.

Sander, a trained import-export merchant, has been with BASF for 25 years. He joined the company as Marketing and Product Manager in 1987, and subsequently held executive-level positions at various BASF operating divisions in both Germany and abroad.

Sander will succeed Simon Medley, who has decided to leave BASF to pursue his career outside the group.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.